nach oben

Current Infectious Disease Reports

Erschienen in:

01.10.2012 | Sepsis (J Russell, Section Editor)

Management of Acute Renal Dysfunction in Sepsis

verfasst von: Federico Nalesso, Zaccaria Ricci, Claudio Ronco

Erschienen in: Current Infectious Disease Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Acute kidney injury (AKI) often complicates sepsis, leading to greater complexity and a worsening prognosis. Advances in the clinical management of sepsis may have secondary benefits with respect to renal outcomes. In critically ill patients, this disorder typically produces multiple organ dysfunction. Among the several disorders encountered in sepsis, AKI is one of the most important because it is a life-threatening condition, increases the complexity and cost of care, and is an independent risk factor for mortality. The potential interventions in sepsis-related AKI consist of effective prevention/protection strategies for the kidney in patients at risk, early recognition and attenuation of renal damage, pathophysiology-driven pharmacologic support, efficient extracorporeal blood purification therapy, and strategies that promote recovery of renal function. Existing and hybrid extracorporeal therapies are being investigated not only as means to replace lost kidney function, but also to modulate the immune response to sepsis.

Parmar A, Langenberg C, Wan L, et al. Epidemiology of septic acute kidney injury. Curr Drug Targets. 2009;10:1169–78.PubMedCrossRef

Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012;78:1–8.PubMed

Parikh A, Shaw A. The economics of renal failure and kidney disease in critically ill patients. Crit Care Clin. 2012;28:99–111.PubMedCrossRef

Oppert M, Engel C, Brunkhorst FM, et al. Acute renal failure in patients with severe sepsis and septic shock–a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008;23:904–9.PubMedCrossRef

Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002;8:509–14.PubMedCrossRef

Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med. 2007;33:409–13.PubMedCrossRef

Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913–7.PubMedCrossRef

Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. October 25, 2007.

Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73.PubMedCrossRef

10.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest. 1992;101:1644–55.PubMedCrossRef

11.

Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care. 1994;9:72–81.PubMedCrossRef

12.

Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73(5):538–46.PubMedCrossRef

13.

Bellomo R, Wan L, May C. Managing septic acute renal failure: “fill and spill”? “squeeze and diurese”? or “block Bax to the max”? Crit Care Resusc. 2004;6:12–6.PubMed

14.

Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef

15.

Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.PubMedCrossRef

16.

Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:904–12.PubMedCrossRef

17.

• Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752–61. This paper highlights the role of N-GAL in the early diagnosis of AKI.PubMedCrossRef

18.

Liangos O. Drugs and AKI. Minerva Urol Nefrol. 2012;64:51–62.PubMed

19.

Hilton AK, Bellomo R. A critique of fluid bolus resuscitation in severe sepsis. Crit Care. 2012;16:302.PubMedCrossRef

20.

Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.PubMedCrossRef

21.

•• SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37:86–96. This paper is important since it provides very important information about the fluids theraphy of sepsis.CrossRef

22.

Friedman G, Jankowski S, Shahla M, Gomez J, Vincent JL. Hemodynamic effect of 6 % and 10 % hydroxyethyl starch solutions versus 4 % albumin solution in septic patients. J Clin Anesth. 2008;20:528–33.PubMedCrossRef

23.

Fang ZX, Li YF, Zhou XQ, Zhang Z, Zhang JS, Xia HM, Xing GP, Shu WP, Shen L, Yin GQ. Effects of resuscitation with crystalloud fluids on cardiac function in patients with severe sepsis. BMC Infect Dis. 2008;8:50.PubMedCrossRef

24.

Hartog CS, Brunkhorst FM, Engel C, et al. Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use? Wien Klin Wochenschr. 2011;123:145–55.PubMedCrossRef

25.

Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2010;20:CD007594.

26.

Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group: early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.PubMedCrossRef

27.

Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333:1025–32.PubMedCrossRef

28.

Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med. 2003;29:1774–81.PubMedCrossRef

29.

Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–87.PubMedCrossRef

30.

Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 2010;36:83–91.PubMedCrossRef

31.

Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med. 2005;33:2451–6.PubMedCrossRef

32.

•• Lentini P, de Cal M, Clementi A, et al. Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. Crit Care Res Pract. 2012;2012:856401. This paper is important since provide some important informations about some interesting biomarkers to early diagnose AKI.PubMed

33.

Goldstein SL. Acute kidney injury biomarkers: renal angina and the need for a renal troponin I. BMC Med. 2011;9:135.PubMedCrossRef

34.

Bellomo R. How to feed patients with renal dysfunction. Blood Purif. 2002;20:296–303.PubMedCrossRef

35.

Lipcsey M, Bellomo R. Septic acute kidney injury: hemodynamic syndrome, inflammatory disorder, or both? Crit Care. 2011;15:1008.PubMedCrossRef

36.

Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care. 2005;9:R363–74.PubMedCrossRef

37.

Ishikawa K, Bellomo R, May CN. The impact of intrarenal nitric oxide synthase inhibition on renal blood flow and function in mild and severe hyperdynamic sepsis. Crit Care Med. 2011;39:770–6.PubMedCrossRef

38.

Benes J, Chvojka J, Sykora R, Radej J, Krouzecky A, Novak I, Matejovic M. Searching for mechanisms that matter in early septic acute kidney injury: an experimental study. Crit Care. 2011;15:R256.PubMedCrossRef

39.

•• Ricci Z, Polito A, Polito A, Ronco C. The implications and management of septic acute kidney injury. Nat Rev Nephrol. 2011;7:218–25. This paper hightlights the management of AKI in septic patients and provide important information for the treatments of sepsis related kidney injury.PubMedCrossRef

40.

Mehta RL, Pascual MT, Soroko S, Chertow GM, PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–53.PubMedCrossRef

41.

Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6:966–73.PubMedCrossRef

42.

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–75.CrossRef

43.

Bagshaw SM, Gibney RT, McAlister FA, Bellomo R. The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury. Trials. 2010;11:50.PubMedCrossRef

44.

Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356:2139–43.PubMedCrossRef

45.

Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin- like growth factor I in patients with acute renal failure. Kidney Int. 1999;55:2423–32.PubMedCrossRef

46.

Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA. 2011;306:2439–40.PubMedCrossRef

47.

Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol. 2007;2:356–65.PubMedCrossRef

48.

Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14.PubMedCrossRef

49.

Gotloib L, Barzilay E, Shustak A, Lev A. Sequential hemofiltration in nonoliguric high capillary permeability pulmonary edema of severe sepsis: preliminary report. Crit Care Med. 1984;12:997–1000.PubMedCrossRef

50.

De Vriese AS, Colardyn FA, Philippe JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846–53.PubMed

51.

De Vriese AS, Vanholder RC, Pascual M, et al. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med. 1999;25:903–10.PubMedCrossRef

52.

Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.PubMedCrossRef

53.

Huang H, Yao T, Wang W, et al. Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg. 2003;76:136–40.PubMedCrossRef

54.

Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis. 2001;37:457–66.PubMedCrossRef

55.

Yekebas EF, Eisenberger CF, Ohnesorge H, et al. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med. 2001;29:1423–30.PubMedCrossRef

56.

Righetti M, Ferrario GM, Milani S, et al. A single centre study about the effects of HFR on anemia. G Ital Nefrol. 2004;21 Suppl 30:S168–71.PubMed

57.

Tarakcioglu M, Erbagci AB, Usalan C, et al. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediat Inflamm. 2003;12:15–9.CrossRef

58.

Fiaccadori E, Maggiore U, Parenti E, et al. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant. 2007;22:529–37.PubMedCrossRef

59.

Marshall MR, Golper TA, Shaver MJ, et al. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis. 2002;39:556–70.PubMedCrossRef

60.

Van Biesen W, Veys N, Vanholder R. Intermittent hemodialysis for renal replacement therapy in intensive care: new evidence for old truths. Contrib Nephrol. 2007;156:304–8.PubMedCrossRef

61.

Lonnemann G, Bechstein M, Linnenweber S, et al. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl. 1999;(72):S84–S87.

62.

Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486–92.PubMedCrossRef

63.

Bouman CS, Oudemans-van Straaten HM, et al. Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J Crit Care. 2007;22:1–12.PubMedCrossRef

64.

Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.PubMedCrossRef

65.

Cruz DN, Bellomo R, Ronco C. Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol. 2007;156:444–51.PubMedCrossRef

66.

Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.PubMedCrossRef

67.

• Antonelli M, Fumagalli R, Cruz DN, EUPHAS Study Group, et al. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial. Contrib Nephrol. 2010;167:83–90. Epub 2010 Jun 1. This paper highlight the role of PMX in endotoxin removal and the interesting results in using this device to treat patients with Sepsis from Gram negative bacteria.PubMedCrossRef

68.

Uchino S, Bellomo R, Goldsmith D, et al. A new technique for cytokine removal. Intensive Care Med. 2002;28:651–5.PubMedCrossRef

69.

Lee PA, Weger GW, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med. 1998;26:730–7.PubMedCrossRef

70.

Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. 2003;18:2570–6.PubMedCrossRef

71.

Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. 2006;34:2099–104.PubMedCrossRef

72.

Haase M, Bellomo R, Baldwin I, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis. 2007;50:296–304.PubMedCrossRef

73.

Peng ZY, Kiss JE, Cortese-Hasset A, et al. Plasma filtration on mediators of thrombotic microangiopathy: an in vitro study. Int J Artif Organs. 2007;30:401–6.PubMed

74.

Formica M, Inguaggiato P, Bainotti S, Wratten ML. Coupled plasma filtration adsorption. Contrib Nephrol. 2007;156:405–10.PubMedCrossRef

75.

Bellomo R, Tetta C, Ronco C. Coupled plasma filtration adsorption. Intensive Care Med. 2003;29:1222–8.PubMedCrossRef

76.

Ronco C, Brendolan A, Lonnemann G, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002;30:1250–5.PubMedCrossRef

77.

Uchino S, Bellomo R, Morimatsu H, et al. A worldwide practice survey—The Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Med. 2007;33:1563–70.PubMedCrossRef

78.

Uchino S, Bellomo R, Kellum JA, et al. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators Writing Committee: patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30:281–92.PubMed

79.

Van Wert R, Friedrich JO, Scales DC, University of Toronto Acute Kidney Injury Research Group, et al. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med. 2010;38:1360–9.PubMed

80.

RENAL Study Investigators, Bellomo R, Cass A, Cole L, et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renalfailure. Blood Purif. 2008;26(5):407–16. Review.PubMedCrossRef

81.

Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563–70.PubMedCrossRef

Titel: Management of Acute Renal Dysfunction in Sepsis
verfasst von: Federico Nalesso
Zaccaria Ricci
Claudio Ronco
Publikationsdatum: 01.10.2012
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 5/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-012-0274-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Variability Analysis and the Diagnosis, Management, and Treatment of Sepsis

From Ulcer to Infection: An Update on Clinical Practice and Adjunctive Treatments of Diabetic Foot Ulcers

Toll-Like Receptors and Opportunities for New Sepsis Therapeutics

Prevention of Surgical Site Infections in Bone and Joint Procedures

Cardiovascular Management of Septic Shock in 2012